Vaxcyte, Inc. (PCVX) Makes Strides on Pneumonia Treatment, Plots Coverage Extension [Yahoo! Finance]
Vaxcyte Doses First Participants in the OPUS Phase 3, Noninferiority Trial Evaluating VAX-31 for the Prevention of Invasive Pneumococcal Disease and Pneumonia in Adults
Vaxcyte (PCVX): Evaluating Valuation After a 48% Three-Month Share Price Rebound [Yahoo! Finance]
Vaxcyte (NASDAQ:PCVX) was given a new $77.00 price target on by analysts at Leerink Partners.
Medicxi Announces €500 Million Fund V [Yahoo! Finance]